Received Aug 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (FOREIGN) | MERCK & CO. INC. | 1 | — | OT |
| HEP | HEP B (FOREIGN) | MERCK & CO. INC. | 2 | — | OT |
No other AE; HCP calling to report a patient who received HEPTAVAX-II (RECOMBIVAX HB) in (withheld) on 27MAY2024 and second dose on 25JUN2025 would like to receive her 3rd dose here in (withheld). She will be receiving a 3rd dose in the form of ENGERIX-B today 28JUL2025.; This spontaneous report was received from a pharmacist and refers to a(n) 37-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 27-May-2024, in another country, the patient was vaccinated with the first dose of with Hepatitis B Vaccine (Recombinant) (HEPTAVAX-II) (RECOMBIVAX HB). On 25-Jun-2025, the patient received the second dose of with Hepatitis B Vaccine (Recombinant) (HEPTAVAX-II) (RECOMBIVAX HB) (Inappropriate schedule of vaccine administration). Both doses were administered by Unknown route as prophylaxis (anatomical site, lot # and expiration date were not reported). On 28-Jul-2025, she would receive her 3rd dose in the reporter's country, but in the form of ENGERIX-B. No other information provided. No other AE/No PQC. Lot number is being requested and will be submitted if received.